Member Info for Bebeto

Evgen Pharma held a double blind trial at Southampton and the bod didn't have a bloody clue of results before end of trial.

SNG 001 needs to be administered earlier in the cycle, due to the max viral load happening a lot sooner, when symptoms start. Ideally a positive test result with no symptoms would be the Goldilocks time.

Double blind, they'll be no leaks the data set recognised worldwide.

https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001023-14/GB/

The shareprice stayed within it's range this week, which underpins this level.

SNG001 proven to provent against SARS-CoV in the laboratory.
SARS-CoV has 50% of the genome of Covid-19 (SARS-CoV2)
SNG001 in my opinion, should prevent at least 50% of Covid-19, so I am expecting a positive result from the trial.

Have a lovely weekend.

UOG is in a strong position compared to others in the sector, shareprice is yet to reflect this.

One for the bottom drawer, will add on dips.

They won't have a mining lease at this stage but :

"The holder of an exploration licence may in accordance with the licence conditions, extract or disturb up to 1000 tonnes of material from the ground which includes overburden."

The more Newcrest keeps putting the drill bit in the ground the clearer the picture will be all round.

Looking forward to seeing their results.

Shareprice has found its level range now, should move up going into June. Chance of Success is a high percentage IMO

Smart move for the new chairman, we're going to be the only "Eddie Stobart" in the market and saving £3M per year off the balance sheet.

This share has a second chance insurance policy, so the odds are better. IMO

Optiva has a per share valuation of 4.3p for the acquired Egypt business alone, compared to a market price of 1.65p – whereas the total sum-of-parts valuation rises to 10.4p once other production and more prospective exploration assets are factored in.

Gray said the broker’s valuation “demonstrates that the company’s current market capitalisation is well covered by our valuation of Egypt alone.

“With cash flow expected to be augmented from initial cash production from the Selva field in Italy later in 2020 and further progress anticipated with regards to United’s earlier stage assets, we believe that the company comfortably justifies our 10.4p valuation for the wider portfolio.”

Market makers earn their incomes from taking trades, therefore they are always available for a trade. They do choke the flow of trades by using the spread & NT and they can do flash drops taking every stop loss out to accumulate more shares to trade, but lower the free float the more volatile the shareprice will be.

Enough buying pressure would push through 10p , with MRE the shareprice will open above for sure.

Extract from 30th April RNS:

"Results from this part of the study are still expected in June 2020"

So the hospital and home results will be released in June. We know it's a 14 day dosage for trial, so the last participant probably hasn't finished treatment.

One thing is for sure, they can't hold back on results as all the data has to be verified and results published.

Usually RNS update saying last participant has completed trial and now gathering all data , which will be analyzed and verified (independently) results in a few weeks.

Something along those lines.

Interesting article to read and thanks. At this stage there's still a lot of variables at play including how much Newcrest would actually intend on mining. The timely, Hannam report gave us high grade 4.4M Oz "in the bag" which propped up the shareprice. Look forward to seeing the MRE and the shareprice will look after itself.

Shareprice seems stronger than before now too.

These investing companies, have their own agendas & criteria's of. They drip feed trades because of the size of their position's liquidity as they take an aggregate of all their trades. It's fair to assume that these companies (in these times) has taken losses and with the upcoming recession ahead, they'll also need to get into a decent cash position, to help their situation and take on opportunities. Private investors should take note.

It's not rocket science, If we still have a big seller in the background, then we can all clearly see the area they start selling and when they stop selling down. Support & resistance evaporates in seconds.

No news then the shareprice will remain 49-59 region, volume is tailing off with most of the heavy selling already happened.

Soaking up the free float, bodes well.